Non-Hormonal Treatment of Vasomotor Symptoms
On this page
Direct answer
Non-hormonal treatment of vasomotor symptoms uses drugs that reduce hot flushes and night sweats without oestrogen, chiefly low-dose paroxetine, venlafaxine, gabapentin, clonidine and the neurokinin-3 receptor antagonist fezolinetant. These options suit women who cannot take hormone therapy, such as those with a history of breast cancer or unexplained vaginal bleeding. Lifestyle measures and cognitive behavioural therapy remain part of the overall plan.
What you must remember
- Hormone therapy first: It remains the most effective treatment, so non-hormonal drugs are chosen when it is contraindicated or declined.
- Low-dose paroxetine: Paroxetine 7.5 mg daily is approved specifically for vasomotor symptoms by the US FDA; availability and licensing differ elsewhere.
- Venlafaxine: An SNRI supported by trial evidence for hot flushes; nausea and dose-related hypertension limit its use.
- Gabapentin: Useful when night sweats disturb sleep; dizziness and sedation are the main adverse effects.
- Clonidine: An alpha-2 agonist with modest benefit; hypotension and dry mouth limit tolerance.
- Fezolinetant: A neurokinin-3 receptor antagonist acting on hypothalamic KNDy neurons, with liver enzyme monitoring as per labelling.
- Lifestyle and CBT: Cooling measures, avoiding triggers and cognitive behavioural therapy reduce the distress of symptoms.
A comparison of the main non-hormonal agents
The agents differ mainly in mechanism, side effects and interactions. Choose by the woman's comorbidities as well as her symptom pattern.
| Agent | Mechanism | Main caution |
|---|---|---|
| Paroxetine 7.5 mg | SSRI, low dose | Strong CYP2D6 inhibition |
| Venlafaxine | SNRI | Hypertension, nausea |
| Gabapentin | Calcium channel modulator | Dizziness, sedation |
| Clonidine | Alpha-2 agonist | Hypotension, dry mouth |
| Fezolinetant | NK3 receptor antagonist | Liver enzyme monitoring |
Paroxetine and venlafaxine suit women who also have low mood or anxiety, whereas gabapentin suits night sweats that disturb sleep. Fezolinetant targets the thermoregulatory pathway directly, but its use needs liver enzyme monitoring as per the product labelling.
Start at the lowest dose and review response before escalating, because most adverse effects appear early. A short diary of flush frequency and sleep disturbance lets the benefit be weighed against side effects over several weeks. Some women need to try two agents before settling on one, so a second option should be planned in advance.
Selection traps the exam favours
Most mistakes here come from drug interactions and from assuming a drug is licensed for a symptom it treats.
- Trap: Prescribing paroxetine to a woman on tamoxifen for breast cancer. Correct: Paroxetine strongly inhibits CYP2D6, which activates tamoxifen, so a drug without that effect, such as gabapentin, is preferred after oncology review.
- Trap: Assuming every SSRI is licensed for hot flushes. Correct: Low-dose paroxetine has specific FDA approval for hot flushes, while escitalopram is used off-label with supporting evidence.
- Trap: Choosing clonidine as the main treatment for severe flushes. Correct: Its benefit is modest and hypotension limits use, so it is a later-line option.
- Trap: Calling fezolinetant a hormone product. Correct: It is non-hormonal and acts on KNDy neurons, so it does not treat urogenital atrophy or bone loss.
Frequently asked questions
Which antidepressant is specifically licensed for menopausal hot flushes?
Low-dose paroxetine, 7.5 mg daily, is approved specifically for vasomotor symptoms by the US FDA, although licensing and availability vary by country. Other agents such as escitalopram and venlafaxine are used off-label with supporting evidence. Paroxetine's strong CYP2D6 inhibition is the key interaction to check.
Why is paroxetine avoided in women taking tamoxifen?
Paroxetine strongly inhibits CYP2D6, the enzyme that converts tamoxifen into its active metabolite endoxifen. Reduced endoxifen can weaken tamoxifen's anti-oestrogen effect. Drugs with fewer CYP2D6 interactions, such as gabapentin, are generally preferred in these women after oncology review.
How does fezolinetant reduce hot flushes?
Fezolinetant is a neurokinin-3 receptor antagonist. It blocks signalling in KNDy neurons in the hypothalamus, which become overactive when oestrogen falls. Liver enzymes should be monitored during treatment, as directed by the product labelling.
Which non-hormonal drug suits night sweats that disturb sleep?
Gabapentin suits night sweats that disturb sleep, because it can be taken at bedtime and reduces vasomotor episodes. Dizziness and sedation are its common adverse effects. Gabapentin should be started at a low dose and titrated slowly as tolerated.
Is black cohosh an effective non-hormonal option for hot flushes?
Black cohosh and other herbal products have inconsistent evidence and variable product content, so they are not standard treatment. Rare liver injury has been reported with black cohosh preparations. Cognitive behavioural therapy and lifestyle measures have more reliable evidence in this setting.